enGene Therapeutics Warrants
ENGNW
11 hedge funds and large institutions have $1.54M invested in enGene Therapeutics Warrants in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
2.74% more ownership
Funds ownership: 48.54% → 51.28% (+2.7%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
88% less capital invested
Capital invested by funds: $12.9M → $1.54M (-$11.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$347K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$34.5K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$32.8K |
| 4 |
SG
StoneX Group
New York
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tenor Capital Management
New York
|
-$140K |
| 2 |
SCM
Saba Capital Management
New York
|
-$101K |
| 3 |
ICM
Ionic Capital Management
New York
|
-$42.4K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$11.4K |
| 5 |
CS
Clear Street
New York
|
-$104 |
ENGNW Hedge Fund Activity: Q2 2026 in Review
11 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q2 2026, worth a combined $1.54M — down 88% from $12.9M a quarter earlier.
Fund positioning in ENGNW was balanced in Q2 2026: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Caption Management, opening a new position worth an estimated $347K. The largest seller was Tenor Capital Management, exiting entirely with an estimated $140K sold.
- 11 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $1.54M of enGene Therapeutics Warrants stock for Q2 2026, down 88% quarter-over-quarter.
- 3 funds opened new enGene Therapeutics Warrants positions in Q2 2026 and 3 closed out, a net change of 0 holders.
- The largest enGene Therapeutics Warrants buyer in Q2 2026 was Caption Management, an estimated $347K added.
- The largest enGene Therapeutics Warrants seller in Q2 2026 was Tenor Capital Management, an estimated $140K sold.
Based on aggregated 13F filings for Q2 2026.